Scarica l'app Stockscreener
23.69
1.32%
0.28
Precedente Chiudi:
$23.41
Aprire:
$23.28
Volume 24 ore:
210.37K
Relative Volume:
0.23
Capitalizzazione di mercato:
$1.35B
Reddito:
-
Utile/perdita netta:
$-107.85M
Rapporto P/E:
-10.72
EPS:
-2.21
Flusso di cassa netto:
$-106.82M
1 W Prestazione:
+10.89%
1M Prestazione:
-10.93%
6M Prestazione:
-44.80%
1 anno Prestazione:
-42.68%
Intervallo 1D:
$23.04
$23.88
Intervallo di 1 settimana:
$22.12
$23.90
Portata 52W:
$18.53
$51.61
Vera Therapeutics Inc Stock (VERA) Company Profile
Nome
Vera Therapeutics Inc
Settore
Industria
Telefono
650-770-0077
Indirizzo
2000 SIERRA POINT PARKWAY, SUITE 1200, BRISBANE
Confronta VERA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VERA
Vera Therapeutics Inc
|
23.71 | 1.35B | 0 | -107.85M | -106.82M | -2.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.00 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
630.58 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.42 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.30 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Vera Therapeutics Inc Stock (VERA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2025-01-28 | Iniziato | Goldman | Buy |
| 2024-11-21 | Iniziato | Wells Fargo | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-25 | Iniziato | Oppenheimer | Outperform |
| 2024-01-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-12-18 | Iniziato | Raymond James | Outperform |
| 2023-11-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-16 | Iniziato | Guggenheim | Buy |
| 2023-01-04 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-04 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-07-12 | Iniziato | JP Morgan | Overweight |
| 2022-05-02 | Iniziato | H.C. Wainwright | Buy |
| 2022-04-19 | Iniziato | Wedbush | Outperform |
Mostra tutto
Vera Therapeutics Inc Borsa (VERA) Ultime notizie
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Wells Fargo & Company MN - Defense World
A stock that deserves closer examination: Vera Therapeutics Inc (VERA) - uspostnews.com
Traders Purchase Large Volume of Call Options on Vera Therapeutics (NASDAQ:VERA) - Defense World
Vera Therapeutics Inc (VERA): What Are The Positives? - Marketing Sentinel
When (VERA) Moves Investors should Listen - news.stocktradersdaily.com
Vera Therapeutics Inc (NASDAQ: VERA) Received An -47.05% Loss In 6 Months – Here’s What To Expect - Marketing Sentinel
Alliancebernstein L.P. Boosts Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (VERA) Stock Sees After-Market Boost - Stocks Telegraph
After-Market Momentum Builds For ASP Isotopes (ASPI) Amid Secondary Listing News - Stocks Telegraph
Wellington Management Group LLP Trims Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by JPMorgan Chase & Co. - Defense World
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
Polycythemia Vera Therapeutics Market Set to Witness - openPR.com
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch - Yahoo Finance
Vanguard Group Inc. Acquires 369,387 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Corebridge Financial Inc. - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Analysts - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics completes enrollment for IgAN drug trial By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $21.44 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $21.44 - Investing.com India
Vera Therapeutics completes enrollment for IgAN drug trial - Investing.com Australia
Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept - TipRanks
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN - GlobeNewswire
Is Vera Therapeutics Inc (VERA) a threat to investors? - uspostnews.com
Vera Therapeutics Inc [VERA] stock was sold by Fordyce Marshall at the price of US$0.3 million - knoxdaily.com
Teacher Retirement System of Texas Acquires 3,942 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics (NASDAQ:VERA) Reaches New 1-Year LowWhat's Next? - MarketBeat
69,724 Shares in Vera Therapeutics, Inc. (NASDAQ:VERA) Bought by Raymond James Financial Inc. - Defense World
Vera Therapeutics stock hits 52-week low at $25.97 By Investing.com - Investing.com South Africa
Vera Therapeutics stock hits 52-week low at $25.97 - Investing.com
Vera Therapeutics validates Fair Value bearish call with 42% decline By Investing.com - Investing.com UK
Swiss National Bank Purchases 15,700 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Relative Strength Alert For Vera Therapeutics - Nasdaq
AlphaQuest LLC Takes Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Bought by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Acquires 7,895 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Arizona State Retirement System Has $532,000 Position in Vera Therapeutics, Inc. (NASDAQ:VERA) - The AM Reporter
Is Vera Therapeutics (NASDAQ:VERA) Weighed On By Its Debt Load? - simplywall.st
Victory Capital Management Inc. Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA) - Defense World
Vera Therapeutics, Inc. (NASDAQ:VERA) Given Average Recommendation of “Buy” by Analysts - Defense World
Vera Therapeutics (VERA) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Vera Therapeutics Growth Accelerates: 9 Strategic Hires Secure Equity Package Worth $2.3M - StockTitan
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
What is HC Wainwright’s Estimate for VERA FY2025 Earnings? - Defense World
Vera Therapeutics Inc (NASDAQ: VERA) Has Dropped -36.17% So Far This Year. Does That Mean Trouble Ahead? - Marketing Sentinel
Vera Therapeutics: Does The Earlier Otsuka Launch Harm Its Prospects Much? - Seeking Alpha
Cantor Fitzgerald Analysts Lower Earnings Estimates for VERA - Defense World
JPMorgan Chase & Co. Has Lowered Expectations for Vera Therapeutics (NASDAQ:VERA) Stock Price - Defense World
Vera Therapeutics Inc Azioni (VERA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vera Therapeutics Inc Azioni (VERA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fordyce Marshall | PRESIDENT AND CEO |
Feb 26 '25 |
Sale |
27.65 |
9,075 |
250,882 |
204,665 |
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):